Global Neprilysin Market Analysis (2026–2036)

Western Market Research estimates that the Global Neprilysin Market was valued at USD XXXX million in 2025 and is projected to reach USD XXXX million by 2036, expanding at a CAGR of XX% during the forecast period from 2026 to 2036.

Neprilysin is a zinc-dependent metalloprotease enzyme involved in the degradation of several biologically active peptides, including natriuretic peptides, bradykinin, and amyloid beta peptides. Neprilysin inhibitors have gained significant attention in the pharmaceutical industry due to their therapeutic potential in treating cardiovascular diseases, neurological disorders, and chronic pain conditions.

The increasing prevalence of cardiovascular diseases, particularly heart failure and hypertension, is a major factor contributing to the growth of the neprilysin market. Additionally, continuous advancements in drug discovery and increasing research activities focused on neprilysin inhibition are supporting the development of new therapeutic drugs.

Pharmaceutical companies and research institutions are investing heavily in developing novel neprilysin inhibitor compounds for a wide range of clinical applications. As a result, the global neprilysin market is expected to experience steady growth throughout the forecast period.

Impact of COVID-19 on the Neprilysin Market

The COVID-19 pandemic had mixed effects on the pharmaceutical industry. While healthcare systems were primarily focused on pandemic management, ongoing research in cardiovascular and neurological treatments continued to progress.

Key impacts included:

• Temporary delays in clinical trials for cardiovascular therapies

• Disruptions in pharmaceutical supply chains

• Reduced hospital visits for non-emergency treatments

• Increased research focus on cardiovascular complications associated with COVID-19

Despite short-term disruptions, the demand for cardiovascular therapeutics remained strong, allowing the neprilysin market to maintain steady long-term growth prospects.

Global Neprilysin Market Segmentation

By Drug Type

• TD-0714

• STR-324

• PL-265

• LHW-090

• Sacubitril-Based Therapies

• Other Neprilysin Inhibitor Compounds

By Drug Class

• Neprilysin Inhibitors

• Angiotensin Receptor–Neprilysin Inhibitors (ARNI)

• Combination Cardiovascular Therapies

By Application

• Acute Heart Failure

• Chronic Heart Failure

• Hypertension

• Alzheimer’s Disease

• Cancer Pain Management

• Cardiovascular Disorders

• Neurological Disorders

• Other Therapeutic Applications

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

By End User

• Hospitals

• Cardiology Clinics

• Neurology Clinics

• Research Institutes

• Pharmaceutical Research Laboratories

Segment Analysis

Drug Type Segment

Sacubitril-based neprilysin inhibitors currently dominate the market due to their widespread use in treating heart failure and other cardiovascular disorders.

Drug Class Segment

Angiotensin receptor–neprilysin inhibitors (ARNI) represent one of the most promising therapeutic classes in cardiovascular medicine, providing improved clinical outcomes compared with traditional treatments.

Application Segment

Heart failure treatment accounts for the largest share of the market due to the increasing global burden of cardiovascular diseases.

Distribution Channel Segment

Hospital pharmacies represent the primary distribution channel due to the specialized nature of cardiovascular treatments.

Regional Analysis

North America

North America dominates the neprilysin market due to advanced healthcare infrastructure, strong pharmaceutical research capabilities, and high prevalence of cardiovascular diseases. The United States leads the region with strong adoption of innovative cardiovascular therapies.

Europe

Europe represents a significant market supported by robust healthcare systems and increasing demand for advanced heart failure treatments. Countries such as Germany, France, and the United Kingdom are major contributors to regional growth.

Asia-Pacific

Asia-Pacific is expected to experience significant growth during the forecast period. Increasing cardiovascular disease prevalence, expanding pharmaceutical industries, and improving healthcare infrastructure in China, India, Japan, and South Korea are driving regional market expansion.

South America

South America is witnessing gradual growth in the cardiovascular pharmaceutical market due to improving healthcare access and rising awareness of advanced treatment options.

Middle East & Africa

The market in this region is developing steadily as healthcare investments increase and pharmaceutical distribution networks expand.

Top Key Players in the Neprilysin Market

Major companies operating in the global neprilysin market include:

• Novartis AG

• Bioprojet SCR

• Pharmaleads SA

• Theravance Biopharma Inc.

• Pfizer Inc.

• AstraZeneca plc

• Bayer AG

• Johnson & Johnson

• Merck & Co., Inc.

• Sanofi SA

• Bristol Myers Squibb

• Takeda Pharmaceutical Company Limited

• Eli Lilly and Company

• GlaxoSmithKline plc

These companies are actively involved in drug development, clinical research, and strategic collaborations to strengthen their market positions.

Porter’s Five Forces Analysis

Competitive Rivalry – Moderate to High

The market includes several global pharmaceutical companies engaged in developing neprilysin inhibitor therapies, leading to increasing competition in drug innovation.

Threat of New Entrants – Low

The pharmaceutical industry requires significant research investment, clinical trials, and regulatory approvals, creating strong barriers for new entrants.

Bargaining Power of Suppliers – Moderate

Suppliers providing pharmaceutical raw materials and active pharmaceutical ingredients (APIs) have moderate influence on production costs.

Bargaining Power of Buyers – Moderate

Hospitals, healthcare providers, and government healthcare programs influence drug pricing through reimbursement policies and procurement agreements.

Threat of Substitutes – Moderate

Alternative cardiovascular medications and treatment methods can serve as substitutes in certain therapeutic situations.

SWOT Analysis

Strengths

• Strong clinical efficacy of neprilysin inhibitor therapies

• Increasing demand for advanced cardiovascular treatments

• Growing pharmaceutical research in neurology and cardiology

Weaknesses

• High cost of drug development and clinical trials

• Complex regulatory approval procedures

• Limited awareness in some emerging markets

Opportunities

• Expansion of combination therapies for heart failure

• Growing research into neurological applications such as Alzheimer’s disease

• Increasing pharmaceutical investment in innovative cardiovascular drugs

Threats

• Patent expiration and generic drug competition

• Strict regulatory approval processes

• Pricing pressure from healthcare reimbursement systems

Market Trend Analysis

Key trends influencing the neprilysin market include:

• Increasing development of combination cardiovascular therapies

• Growing focus on precision medicine for heart failure treatment

• Rising investment in biopharmaceutical research and development

• Expansion of clinical trials for neurological disorder applications

• Adoption of advanced pharmaceutical manufacturing technologies

Market Drivers

• Rising prevalence of cardiovascular diseases worldwide

• Increasing demand for effective heart failure treatments

• Technological advancements in pharmaceutical drug development

• Growing healthcare expenditure globally

• Expanding pharmaceutical research in neurological disorders

Market Challenges

• High cost of cardiovascular drug development

• Long clinical trial timelines

• Regulatory approval complexities

• Competition from alternative cardiovascular medications

Value Chain Analysis

The neprilysin market value chain involves several stages:

1. Raw Material Suppliers – Active pharmaceutical ingredients and chemical compounds

2. Drug Development & Research – Pharmaceutical R&D and clinical trial development

3. Manufacturing – Large-scale pharmaceutical drug production

4. Regulatory Approval – Compliance with global healthcare regulations

5. Distribution – Pharmaceutical wholesalers and distributors

6. Healthcare Providers – Hospitals, cardiology clinics, and pharmacies

7. Patient Treatment & Monitoring – Long-term patient care and therapy management

Efficient coordination across these stages ensures effective drug development and distribution.

Strategic Recommendations for Stakeholders

• Increase investment in research and development of novel neprilysin inhibitors.

• Expand clinical trials exploring neurological applications of neprilysin-targeting drugs.

• Strengthen partnerships between pharmaceutical companies and research institutions.

• Focus on emerging healthcare markets with increasing cardiovascular disease prevalence.

• Improve drug affordability and accessibility through strategic pricing and distribution networks.